Showing results (1311-1320 of 16,812) with videos related to

Sort By:
Pageof 1,682
British Journal of Haematology|December 14, 2019
Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and futureRobert K Hills
British Journal of Haematology|December 12, 2019
Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysisChendan Zhou, Yong Zhuang, Xingjie Lin, et al.
British Journal of Haematology|March 14, 2018
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)Alexandra Smith, Eve Roman, Simon Appleton, et al.
British Journal of Haematology|October 1, 1986
Fibronectin-mediated inhibition of human platelet activation by crosslinked immunoglobulin GM O Spycher, P G Lerch, U E Nydegger, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
British Journal of Haematology|July 6, 2016
GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell diseaseDonna Oksenberg, Kobina Dufu, Mira P Patel, et al.
British Journal of Haematology|July 6, 2016
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauChristian W Eskelund, Arne Kolstad, Mats Jerkeman, et al.
British Journal of Haematology|May 1, 1989
The fate of intravenously injected tissue ferritin in pregnant guinea-pigsR D Lamparelli, B M Friedman, A P MacPhail, et al.
British Journal of Haematology|May 1, 1989
Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemiaJ Holmes, A Jacobs, G Carter, et al.
British Journal of Haematology|May 1, 1989
AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trialC F Hoyle, M de Bastos, K Wheatley, et al.
Pageof 1,682